Elan Pharma International Limited

Recro Pharma, Inc.

Alkermes Pharma Ireland Limited

Baudax Bio, Inc.

Laura Kline

Eugene Rex Cooper

John Dallas Pruitt

Tuula Ryde

Niels Peter Ryde

H William Bosch

Stephen B Ruddy

Gary G Liversidge

Kevin D Ostrander

Rajeev A Jain

Douglas C Hovey

Greta G Cary

Elaine Merisko-Liversidge

The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm.

Nanoparticulate meloxicam formulations

The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.

Nanoparticulate polycosanol formulations and novel polycosanol combinations

Growing community of inventors

Harleysville, PA, United States of America

Laura Kline